References

1. American Diabetes Association, Economic Costs of Diabetes in the US in 2002. Diabetes Care 2003;26:917-932.
    
2. Burton WN, Connerty CM. Evaluation of a worksite-based patient education intervention targeted at employees with diabetes mellitus. J Occup Environ Med 1998;40(8):702–6.
    
3. Centers for Disease Control, Prevalence of Diabetes and Impaired Fasting Glucose in Adults- United States 1999-2000, MMWR September 5, 2003/ 52(35):833-837.
    
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329(14):977–86.
    
5. Diabetes Prevention Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2003;346:393-403.
    
6. Gilmer TP, O'Connor P, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20(12):1847–53.
    
7. Harris,M, Flegal K, Cowie C et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24
    
8. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001;24(1):51-5.
    
9. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM. Diabetes trends in the US: 1990–1998. Diabetes Care 2000;23(9):1278–83.
    
10. Mokdad A, Ford E, Bowman B, Nelson D, Engelgau M, Vinicor F, Marks J. The continuing increase of diabetes in the US. Diabetes Care 2001;24(2):412.
     
11. National Institutes of Health, National Diabetes Fact Sheet: National estimates of diabetes in the US 1997 and 2002 (http://www.cdc.gov/diabetes/pubs/factsheet.htm)
     
12. Ng YC, Jacobs P, Johnson JA. Productivity losses associated with diabetes in the US. Diabetes Care 2001;24(2):257–61.
     
13. Testa MA, Simonsen DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled clinical trial. JAMA 1998;280(17):1490–6.
     
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–53.
     
15. Wagner E, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285(2):182–9.